FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology and represents a host cell for producing an isolated antibody or antigen-binding fragment thereof, which specifically binds PCSK9. Said host cell comprises a nucleic acid molecule encoding a heavy chain variable region (HCVR) region of the PCSK9 antibody comprising the amino acid sequence SEQ ID NO: 90, and a nucleic acid molecule encoding the light chain variable region of the anti-PCSK9 antibody comprising SEQ ID NO: 92. Invention also relates to a method for producing the anti-PCSK9 antibody, a pharmaceutical composition and use of the antibody.
EFFECT: invention widens the range of antibodies specifically binding PCSK9.
6 cl, 14 dwg, 28 tbl, 17 ex
Title | Year | Author | Number |
---|---|---|---|
HIGH-AFFINITY HUMAN ANTI-PCSK9 ANTIBODIES | 2009 |
|
RU2552169C2 |
HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS | 2012 |
|
RU2603481C2 |
PHARMACEUTICAL COMPOSITIONS CONTAINING ANTIBODIES TO HUMAN PCSK9 | 2012 |
|
RU2604139C2 |
ANTI-ANGPTL3 ANTIBODIES AND THEIR APPLICATION | 2012 |
|
RU2620064C2 |
PCSK9 ANTAGONISTS | 2009 |
|
RU2528735C2 |
HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING SPECIFIC GROUPS OF INDIVIDUALS | 2012 |
|
RU2721279C2 |
PCSK9 ANTAGONISTS | 2014 |
|
RU2618869C2 |
ANTIBODIES WITH PH-DEPENDENT ANTIGEN BINDING | 2011 |
|
RU2570729C2 |
ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
HUMANISED ANTI-TAU ANTIBODIES | 2015 |
|
RU2743152C2 |
Authors
Dates
2019-08-20—Published
2009-12-15—Filed